《日本血液学会2023年血液系统恶性肿瘤实用指南：II. 淋巴瘤5. 未另行指定的弥漫性大B细胞淋巴瘤（DLBCL，NOS）》 - Suppr

JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma5. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS).

作者信息

Ohmachi Ken

机构信息

Department of Internal Medicine, Division of Hematology and Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara-City, Kanagawa, 259-1143, Japan.

出版信息

Int J Hematol. 2025 May 28. doi: 10.1007/s12185-025-03997-z.

DOI:10.1007/s12185-025-03997-z

PMID:40434571

Abstract

摘要

相似文献

JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma5. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS).《日本血液学会2023年血液系统恶性肿瘤实用指南：II. 淋巴瘤5. 未另行指定的弥漫性大B细胞淋巴瘤（DLBCL，NOS）》

Int J Hematol. 2025 May 28. doi: 10.1007/s12185-025-03997-z.

JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-5-diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS).《日本血液学会2018年血液系统恶性肿瘤实用指南：II.淋巴瘤-5-弥漫性大B细胞淋巴瘤，非特殊类型（DLBCL，NOS）》

Int J Hematol. 2019 Aug;110(2):131-146. doi: 10.1007/s12185-019-02681-3. Epub 2019 Jun 8.

US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.泊洛妥珠单抗维布妥昔单抗用于既往未治疗的弥漫性大B细胞淋巴瘤的美国成本效益分析。

J Med Econ. 2023 Jan-Dec;26(1):1134-1144. doi: 10.1080/13696998.2023.2254640.

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.波洛沙姆单抗维地滨联合化疗免疫治疗未经治疗的弥漫性大 B 细胞淋巴瘤的成本效益分析。

Blood. 2022 Dec 22;140(25):2697-2708. doi: 10.1182/blood.2022016624.

Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model.对于先前未经治疗的弥漫性大B细胞淋巴瘤，使用泊洛妥珠单抗维达替尼-利妥昔单抗-环磷酰胺、多柔比星和泼尼松（pola-R-CHP）进行一线治疗在中国是否具有成本效益？一项使用马尔可夫模型的成本效益分析。

BMJ Open. 2025 Jan 20;15(1):e086251. doi: 10.1136/bmjopen-2024-086251.

Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.3期POLARIX研究中年龄≥60岁的弥漫性大B细胞淋巴瘤老年患者的亚组分析。

Blood Adv. 2025 May 27;9(10):2489-2499. doi: 10.1182/bloodadvances.2024014707.

Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan.泊洛妥珠单抗维泊妥珠单抗联合利妥昔单抗、环磷酰胺、阿霉素和泼尼松龙治疗日本初治弥漫性大B细胞淋巴瘤的成本效益

J Med Econ. 2023 Jan-Dec;26(1):1122-1133. doi: 10.1080/13696998.2023.2254162.

Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study.泊洛妥珠单抗联合利妥昔单抗、环磷酰胺、多柔比星和泼尼松用于初治弥漫性大B细胞淋巴瘤的疗效与安全性：一项真实世界、多中心、回顾性队列研究

Hematol Oncol. 2025 Jan;43(1):e70017. doi: 10.1002/hon.70017.

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.泊洛妥珠单抗联合化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤

N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.

Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany.在德国未经治疗的弥漫性大 B 细胞淋巴瘤中，与化疗免疫疗法联合使用泊洛妥珠单抗结合物（pola-R-CHP）的成本效益。

Br J Haematol. 2023 Aug;202(4):771-775. doi: 10.1111/bjh.18869. Epub 2023 May 15.

本文引用的文献

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.西达基奥仑赛对比挽救化疗后自体干细胞移植作为二线治疗复发或难治性大 B 细胞淋巴瘤患者的标准治疗（TRANSFORM）：一项开放标签、随机、3 期临床试验的中期分析结果。

Lancet. 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6.

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.泊洛妥珠单抗联合化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤

N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.Tisagenlecleucel 二线治疗或侵袭性 B 细胞淋巴瘤的标准治疗。

N Engl J Med. 2022 Feb 17;386(7):629-639. doi: 10.1056/NEJMoa2116596. Epub 2021 Dec 14.

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.阿基仑赛注射液二线治疗大 B 细胞淋巴瘤。

N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11.

A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL.简化的虚弱评分可预测生存情况，并有助于老年 DLBCL 患者的治疗强度决策。

Blood Adv. 2021 Nov 23;5(22):4771-4782. doi: 10.1182/bloodadvances.2021004777.

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.Tisagenlecleucel 治疗复发或难治性侵袭性 B 细胞淋巴瘤患者的长期临床结局（JULIET）：一项多中心、开放标签、单臂、2 期研究。

Lancet Oncol. 2021 Oct;22(10):1403-1415. doi: 10.1016/S1470-2045(21)00375-2. Epub 2021 Sep 10.

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.利妥昔单抗细胞与 axi-cel 在复发或难治性大 B 细胞淋巴瘤中的匹配调整间接治疗比较。

J Hematol Oncol. 2021 Sep 8;14(1):140. doi: 10.1186/s13045-021-01144-9.

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma.ZUMA-1 研究中 CAR T 细胞对比挽救化疗治疗复发/难治性大 B 细胞淋巴瘤的 2 年疗效比较

Blood Adv. 2021 Oct 26;5(20):4149-4155. doi: 10.1182/bloodadvances.2020003848.

Maintenance therapy for untreated diffuse large B-cell lymphoma: a systematic review and network meta-analysis.未经治疗的弥漫性大B细胞淋巴瘤的维持治疗：一项系统评价和网状Meta分析。

Ther Adv Hematol. 2021 May 29;12:20406207211018894. doi: 10.1177/20406207211018894. eCollection 2021.

Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis.R-COMP 方案对比 R-CHOP 方案治疗弥漫性大 B 细胞淋巴瘤患者的疗效：一项系统评价和单臂荟萃分析。

Crit Rev Oncol Hematol. 2021 Jul;163:103377. doi: 10.1016/j.critrevonc.2021.103377. Epub 2021 Jun 1.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma5. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS).

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献